Marizyme’s first-in-class product, #DuraGraft , stands to dramatically reduce the chances of vein graft failure in #CABG patients—and transform healthcare outcomes for millions each year. Learn more:
marizyme.com

Meet Marizyme’s #pethealth product, #Krillase . This technology is used as a preventative measure for plaque accumulation in pets. Krillase has potential to make significant impact in the pet health industry—learn how: marizyme.com

Coronary artery bypass surgery is the most common surgery performed globally—but it comes with high risks. We’re working to improve patient outcomes—learn how: marizyme.com

#Marizyme $MRZM is a multi-technology biomedical company led by a diverse leadership team with extensive experience.

Learn more: marizyme.com/about-us/

#Marizyme $MRZM has an experienced healthcare team and strategic partners for
distribution regulatory.

Learn more: marizyme.com

Krillase® can be used as a preventative measure for plaque accumulation in
pets. Click the link to read more: marizyme.com

#Marizyme $MRZM is a multi-technology biomedical company with multiple large market opportunities.

Learn more: marizyme.com

Coronary artery bypass grafting #CABG is the single most common cardiac surgery performed globally.

Learn more: marizyme.com

#Marizyme ’s ($MRZM) proprietary product #DuraGraft ® is a biocompatible intraoperative vascular graft storage and flushing solution that maintains endothelial structure and function by preventing oxidative damage and ischemic injury. Learn more:

marizyme.com

Marizyme’s proprietary product for pet health #Krillase ® is a group of proteolytic enzymes made from Antarctic Krill. Click the link to learn more. $MRZM

marizyme.com

With a series of innovative acquisitions completed, #Marizyme $MRZM has been successful in creating a robust #biomedical portfolio:

marizyme.com

#Marizyme ’s ($MRZM) proprietary product #DuraGraft ® is a first-in-class medical
device product used during #CABGsurgery to help lower complications associated
with vein graft disease. Learn more: marizyme.com

#Marizyme $MRZM is working towards our goal of the commercialization and
development and of #MedicalProducts to improve patient outcomes in high impact
diseases. Click the link to learn more: marizyme.com

Products based on Marizyme’s #Krillase ® technology have the ability to remove biofilm from hard and soft tissue and therefore has the potential to be developed into multiple products addressing various indications, such as dental plaque reduction. $MRZM marizyme.com

The #Marizyme $MRZM pipeline includes the following proprietary products and technologies: DuraGraft®, Krillase® , and MATLOC 1™. Click the link to learn more:

marizyme.com

The #Marizyme $MRZM pipeline includes the following proprietary products and technologies: DuraGraft®, Krillase® , and MATLOC 1™. Learn more:

marizyme.com

Meet #Marizyme $MRZM Chief Medical Officer, Steven Brooks, MD, MBA, FACC.
Steven currently serves as CMO for Marizyme, Inc as a healthcare
consultant, publisher, and clinical trialist with experience including regulatory
strategy. Learn more: marizyme.com/about-us/

#Marizyme ’s ($MRZM) proprietary product #DuraGraft ® is a first-in-class medical device product used during #CABGsurgery to help lower complications associated with vein graft disease. Learn more:

marizyme.com

With a series of product and technology acquisitions completed, #Marizyme $MRZM has been successful in creating a robust #LifeScience portfolio:

marizyme.com